InVivoPlus anti-mouse CD40 BP0016-2-R025mg from Bio X Cell

Product Specs
ItemInVivoPlus anti-mouse CD40
CompanyBio X Cell
Price $2,842.00Supplier Page View Company Product Page
Catalog NumberBP0016-2-R025mg
Quantity25 mg
Applicationsin vivo CD40 activation, in vitro B cell stimulation/activation
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
FormatPBS, pH 7.0, Contains no stabilizers or preservatives, Liquid
Purity≥95%, Determined by SDS-PAGE
ReactivityMouse
TargetCD40
IsotypeIgG2a
CloneFGK4.5/FGK45
Hostrat
Antibody TypePrimary Antibody
ImmunogenRecombinant mouse CD40 fusion protein
NCBI Full Gene NameCD40 antigen
NCBI Gene AliasesBp50, GP39, HIGM1, IGM, IMD3, T-BAM, TRAP, Tnfrsf5, p50
ClonalityMonoclonal
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology, Innate Immunity, CD Markers
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze
Molecular Weight150 kDa
ModificationsNo
OriginUnited States

Endotoxin: ≤0.5EU/mg (≤0.0005EU/µg), Determined by LAL gel clotting assay

Quantities Available: 5mg, 25mg, 50mg, 100mg, Additional Custom Sizing Available on bioxcell.com

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bioxcell.com

(1) LAG3⁺ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1⁺ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven ColitisImmunityAugust 21, 2018Bauché D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, Ganal-Vonarburg SC, Wilson DC, McClanahan TK, Malefyt RW, et al.

(2) Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8Nature immunologyDecember 1, 2015Xu H, Chaudhri VK, Wu Z, Biliouris K, Dienger-Stambaugh K, Rochman Y, Singh H.

(3) Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccineProceedings of the National Academy of Sciences of the United States of AmericaSeptember 22, 2015Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA.

(4) DC-SIGN(+) Macrophages Control the Induction of Transplantation ToleranceImmunityJune 16, 2015Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, et al.

(5) Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunityNatureMay 7, 2015Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati GV, et al.

(6) Loss of signalling via Gα13 in germinal centre B-cell-derived lymphomaNatureDecember 11, 2014Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, et al.

(7) Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfectionJournal of immunology (Baltimore, Md. : 1950)November 15, 2014Erickson JJ, Rogers MC, Hastings AK, Tollefson SJ, Williams JV.

(8) Differential kinetics of antigen dependency of CD4+ and CD8+ T cellsJournal of immunology (Baltimore, Md. : 1950)April 15, 2014Rabenstein H, Behrendt AC, Ellwart JW, Naumann R, Horsch M, Beckers J, Obst R.

(9) Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancerCancer immunology researchJanuary 1, 2014Linda C Sandin, Anna Orlova, Erika Gustafsson, Peter Ellmark, Vladimir Tolmachev, Thomas H Tötterman, Sara M Mangsbo

(10) Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletionNature medicineApril 1, 2013Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al.

(11) Primary oligodendrocyte death does not elicit anti-CNS immunityNature neuroscienceFebruary 26, 2012Locatelli G, Wörtge S, Buch T, Ingold B, Frommer F, Sobottka B, Krüger M, Karram K, Bühlmann C, Bechmann I, et al.

InVivoPlus anti-mouse CD40